P2RX1对浆液性卵巢癌患者的预后判断价值及其在免疫浸润机制中的作用

doi:10.3969/j.issn.1004-616x.2024.03.007

癌变·畸变·突变 ›› 2024, Vol. 36 ›› Issue (3): 208-218.doi: 10.3969/j.issn.1004-616x.2024.03.007

P2RX1对浆液性卵巢癌患者的预后判断价值及其在免疫浸润机制中的作用

宋珍明^1,2, 于运亮², 杨金梅², 刘坤², 盖婵婵², 马春宇¹

1. 锦州医科大学基础医学院, 辽宁锦州 121001;
2. 滨州医学院烟台附属医院检验科, 山东烟台 264100

收稿日期:2023-03-04 修回日期:2023-09-26 出版日期:2024-05-30 发布日期:2024-06-05
通讯作者: 马春宇
作者简介:宋珍明，E-mail：szm4770363@163.com;于运亮，E-mail：6667943.good@163.com。
基金资助:
辽宁省教育厅2021年度面上项目(LJKZ0797)；滨州医学院科研启动基金(BY2019KJ43)

Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms

SONG Zhenming^1,2, YU Yunliang², YANG Jinmei², LIU Kun², GAI Chanchan², MA Chunyu¹

1. School of Basic Medical Sciences of Jinzhou Medical University, Jinzhou 121001, Liaoning;
2. Department of Medical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, Shandong, China

Received:2023-03-04 Revised:2023-09-26 Online:2024-05-30 Published:2024-06-05

摘要/Abstract

摘要： 目的：探讨嘌呤能受体X1(P2RX1)与浆液性卵巢癌(OV)患者的临床病理指标及肿瘤微环境免疫细胞浸润的关系，为OV免疫治疗提供新的线索。方法：以OV患者的血清和卵巢癌组织为研究对象，分别以健康成年人和非癌症患者为对照，采用免疫组织化学(IHC)、逆转录荧光定量PCR(RT-qPCR)、酶联免疫吸附试验(ELISA)及生物信息学方法研究OV中P2RX1的表达模式。利用TCGA数据库分析P2RX1 mRNA的表达水平与OV患者不同临床病理指标的相关性；筛选差异基因，分析OV中P2RX1参与的信号通路及其生物学功能；分析P2RX1与免疫细胞浸润丰度、肿瘤免疫相关基因、免疫检查点等的相关性。结果：IHC检测结果显示，P2RX1主要表达于正常卵巢上皮中；RT-qPCR检测结果显示，与非癌组织相比，P2RX1 mRNA在OV中低表达(P<0.05)；ELISA分析结果显示，与正常对照血清相比，P2RX1蛋白在OV患者血清中低表达(P<0.05)。检索TCGA数据库，结果显示高表达P2RX1的OV患者总生存期较长，预后较好(P<0.05)。P2RX1与OV患者的肿瘤纯度和年龄有关(P<0.05)。富集分析结果显示不同P2RX1表达水平的OV患者其差异表达基因主要富集于免疫细胞分化、发育等生物学进程。P2RX1与OV中TGFB1、SLAMF7、CD27等多个免疫检查点有关。P2RX1与B细胞标记包括CD79A、CD79B、CD19明显正相关(均为r>0.4，P<0.05)。结论：在OV中P2RX1的低表达与患者预后不良有关，P2RX1可能参与OV肿瘤微环境免疫细胞浸润、分化等进程。

关键词: 嘌呤能受体X1, 浆液性卵巢癌, 预后, 免疫治疗

Abstract: OBJECTIVE：To investigate correlations between purinergic receptor X1 (P2RX1) and different clinical pathological factors and tumor infiltration parameters in patients with ovarian serous carcinoma (OV)，and to provide new clues for OV immunotherapy. METHODS：Serum samples and tissues were collected from OV patients. Healthy adults and non-cancer patients were used as controls. Immunohistochemistry (IHC)，reverse transcriptation fluorescence quantitative PCR (RT-qPCR)，enzyme-linked immunosorbent assay (ELISA) and bioinformatics methods were used to determine expression patterns of P2RX1 in samples from patients. The TCGA database was used to analyze correlations between expression levels of P2RX1 and different clinicopathological indicators in the patients；to screen differential gene expressions，to identify signaling pathways and biological functions of P2RX1；and to analyze correlations between P2RX1 and immune cell infiltration abundance and tumor immunity. RESULTS：The IHC results show that P2RX1 was mainly expressed in normal ovarian epithelium；the RT-qPCR results show that expression of P2RX1 mRNA was lower in OV than in non-cancer tissues (P<0.05)；the ELISA results show that the expression of P2RX1 protein in the serum of the patients was lower than that of normal healthy adults (P<0.05). Results from analysis of the TCGA database show that patients with higher expression of P2RX1 had longer survival rates and better prognosis (P<0.05) than those with lower expressions. P2RX1 was associated with tumor purity and age of the patients (P<0.05). Results from the enrichment analysis show that the differentially expressed genes of P2RX1 were mainly enriched in biological processes such as immune cell differentiation and development. P2RX1 was found to be associated with multiple immune checkpoints in OV，such as TGFB1，SLAMF7，and CD27. P2RX1 was significantly and positively correlated with B cell marker genes such as CD79A，CD79B，and CD19 in OV (r>0.4，P<0.05). CONCLUSION：Low expression of P2RX1 in OV was associated with poor prognosis in patients. P2RX1 might be involved in processes such as immune cell infiltration and differentiation in the microenvironment of OV patients.

Key words: purinergic receptor X1, ovarian serous carcinoma, prognosis, immunotherapy

中图分类号:

R737.3

宋珍明, 于运亮, 杨金梅, 刘坤, 盖婵婵, 马春宇. P2RX1对浆液性卵巢癌患者的预后判断价值及其在免疫浸润机制中的作用[J]. 癌变·畸变·突变, 2024, 36(3): 208-218.

SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.

参考文献

[1] 汤梓莹, 邓明港, 宇传华, 等. 中国卵巢癌疾病负担现状及趋势分析[J]. 国际妇产科学杂志, 2022, 49(2): 222-227.
[2] SCHOUTROP E, EL-SERAFI I, POIRET T, et al. Mesothelinspecific CAR T cells target ovarian cancer[J]. Cancer Res, 2021, 81(11): 3022-3035.
[3] CHARDIN L, LEARY A. Immunotherapy in ovarian cancer: thinking beyond PD-1/PD-L1[J]. Front Oncol, 2021, 11: 795547.
[4] ZHANG W J. Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy[J]. Purinergic Signal, 2021, 17(1): 151-162.
[5] AKHTARI M, ZARGAR S J, VOJDANIAN M, et al. P2 receptors mRNA expression profiles in macrophages from ankylosing spondylitis patients and healthy individuals[J]. Int J Rheum Dis, 2020, 23(3): 350-357.
[6] HUANG Z, LIU P, ZHU L, et al. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation[J]. Thromb Haemost, 2014, 112(1): 142-150.
[7] LECUT C, FACCINETTO C, DELIERNEUX C, et al. ATPgated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation[J]. J Thromb Haemost, 2012, 10(3): 453-465.
[8] YANG X J, LU B, SUN X Q, et al. ANP32A regulates histone H3 acetylation and promotes leukemogenesis[J]. Leukemia, 2018, 32(7): 1587-1597.
[9] WANG X, HU L P, QIN W T, et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis[J]. Nat Commun, 2021, 12(1): 174.
[10] AUDRITO V. Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils[J]. Purinergic Signal, 2021, 17(2): 173-174.
[11] 于运亮, 封建凯, 姜杰, 等. 宫颈癌中P2RX1的表达与肿瘤浸润的相关性分析[J]. 标记免疫分析与临床, 2022, 29(2): 301-308, 348.
[12] 于运亮, 王莉莉, 李婷, 等. 嘌呤能受体 X1 与肺腺癌预后及免疫细胞浸润的相关性研究[J]. 癌变·畸变·突变, 2022, 34(5): 353-360, 365.
[13] ARAN D, HU Z C, BUTTE A J. xCell: digitally portraying the tissue cellular heterogeneity landscape[J]. Genome Biol, 2017, 18(1): 220.
[14] YANG Y X, LIU L, GUO Z W, et al. Investigation and assessment of neutrophil dysfunction early after severe burn injury[J]. Burns, 2021, 47(8): 1851-1862.
[15] XU Y Y, ZOU B, FAN B J, et al. NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma[J]. Aging, 2022, 14(10): 4471-4485.
[16] 向雨, 张泽宇, 辛华. 趋化因子及其受体对卵巢癌发生发展的作用的研究进展[J]. 广东化工, 2020, 47(9): 129-130.
[17] ANADON C M, YU X Q, HÄNGGI K, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory Tcells[J]. Cancer Cell, 2022, 40(5): 545-557.e13.
[18] PAUTU J L, KUMAR L. Intratumoral T cells and survival in epithelial ovarian cancer[J]. Natl Med J India, 2003, 16(3): 150-151.
[19] WAN C X, KEANY M P, DONG H, et al. Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer[J]. Cancer Res, 2021, 81(1): 158-173.
[20] WANG L, SUN W J, ZHANG G A, et al. T-cell activation is associated with high-grade serous ovarian cancer survival[J]. J Obstet Gynaecol Res, 2022, 48(8): 2189-2197.
[21] KUMAGAI S, TOGASHI Y, KAMADA T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies[J]. Nat Immunol, 2020, 21(11): 1346-1358.
[22] 马驰, 林玲, 胡敏, 等. 肿瘤微环境与卵巢癌耐药的研究进展[J]. 吉林医学, 2018, 39(8): 1557-1560.
[23] SCHREIBER R D, OLD L J, SMYTH M J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
[24] JIANG P, GU S Q, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558.

P2RX1对浆液性卵巢癌患者的预后判断价值及其在免疫浸润机制中的作用

Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马晟, 王希君, 刘振荣, 王雅茹, 胡楠, 荣维淇, 肖汀. 主要促进因子超家族成员2a在肝细胞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2024, 36(3): 187-194.
[2]	张艺, 高含, 郑展越, 谭启涛, 杨敏丽, 孙艳. 基于公共数据库的胶质瘤预后相关基因筛选[J]. 癌变·畸变·突变, 2024, 36(3): 195-201.
[3]	付勇青, 徐三会, 赵岩, 王丽丽. SPP1、DEC1、C1QTNF6蛋白与口腔鳞状细胞癌患者临床病理指标及预后的关系[J]. 癌变·畸变·突变, 2024, 36(2): 107-111,117.
[4]	童晶, 王丹. miR-544a在结直肠癌组织中的表达及其意义[J]. 癌变·畸变·突变, 2024, 36(2): 124-128,137.
[5]	薛松, 胡加海, 董祥宁. PGAM5在胰腺癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2024, 36(1): 29-34.
[6]	王科芳, 陈瑜, 吴陈雨, 刘梅, 汪丽杰, 田建广, 周小会, 许岚. 白细胞介素-17A与雌激素受体α和β在上皮性卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2024, 36(1): 42-47.
[7]	王馨焱, 刘晓玲, 贾军梅. 淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展[J]. 癌变·畸变·突变, 2024, 36(1): 80-83.
[8]	朱文标, 丘波, 谢寿城, 肖焕钦, 刘高敏. 跨膜蛋白79在肝细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2023, 35(6): 426-430.
[9]	许金花, 李静静, 吴国峰, 任亚俊, 王雪, 张骞云. 非小细胞肺癌患者血清miR-146a与TNF-α、Treg的相关性及其对预后判断的价值[J]. 癌变·畸变·突变, 2023, 35(6): 462-466.
[10]	杨上英, 黄明翔, 许德新, 刘加夫, 陈新富. DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析[J]. 癌变·畸变·突变, 2023, 35(6): 467-472.
[11]	高榴, 禹莉. 线粒体转录因子A在肿瘤发生发展中作用的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 485-488.
[12]	呙文静, 邓慧, 宋萍, 张孟贤. 转化生长因子β诱导蛋白在胶质瘤中的表达及生物学功能[J]. 癌变·畸变·突变, 2023, 35(5): 341-348.
[13]	韦来凤, 洪超群, 陈柳伊, 许镒洧, 伍方财. 实验室炎症相关指标的列线图对预测舌鳞状细胞癌患者手术预后的价值[J]. 癌变·畸变·突变, 2023, 35(5): 366-373.
[14]	杨程晴, 崔永辉, 郑紫恒. 结肠癌患者血清中miR-653-5p的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 261-265.
[15]	刘瑞雪, 张力为. 腺苷酸活化蛋白激酶在哈萨克族食管鳞癌组织中的表达及意义[J]. 癌变·畸变·突变, 2023, 35(4): 285-291.